Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in IDH1-or IDH2-Mutant Newly Diagnosed Acute Myeloid Leukemia ( AML) - a Multicenter Cohort Study

被引：0

作者：

Bewersdorf, Jan Philipp ^{[1
]}

Shimony, Shai ^{[2
]}

Shallis, Rory M. ^{[3
]}

Liu, Yiwen ^{[4
]}

Schaefer, Eva Johanna ^{[5
]}

Zeidan, Amer M. ^{[6
,7
]}

Goldberg, Aaron D. ^{[1
]}

Stein, Eytan M. ^{[1
]}

Marcucci, Guido ^{[8
]}

Lindsley, R. Coleman ^{[9
]}

Chen, Evan C. ^{[5
]}

Ramos, Jorge ^{[10
]}

Stein, Anthony Selwyn ^{[11
]}

DeAngelo, Daniel J. ^{[12
]}

Neuberg, Donna S. ^{[4
]}

Stone, Richard M. ^{[12
]}

Ball, Brian J. ^{[10
]}

Stahl, Maximilian ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Harvard Med Sch, DanaFarber Canc Inst, Dept Med Oncol, Boston, MA USA

[3] Yale Univ, Sect Hematol, Dept Internal Med, Yale Sch Med, New Haven, CT USA

[4] DanaFarber Canc Inst, Dept Data Sci, Boston, MA USA

[5] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[6] Yale Univ, Dept Internal Med, Yale Sch Med, New Haven, CT USA

[7] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[8] City Hope Natl Med Ctr & Beckman Res Inst, Dept Hematol Malignancies Translat Sci, Gehr Family Ctr Leukemia Res, Duarte, CA USA

[9] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[10] City Hope Canc Ctr, Duarte, CA USA

[11] City Hope Natl Med Ctr, Duarte, CA USA

[12] Dana Farber Canc Inst, Boston, MA USA

[13] Dana Farber Inst, Boston, MA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174283

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
Wolach, Ofir
Garcia, Jacqueline S.
Desai, Pinkal
Vachhani, Pankit
Zeidner, Joshua F.
Abedin, Sameem
Sweet, Kendra
Lai, Catherine
Moshe, Yakir
Pollyea, Daniel A.
Xavier, Marin
Nachmias, Boaz
Zuckerman, Tsila
Lee, Sangmin
Chen, Evan C.
Bathini, Srilakshmi
Edwards, Wesleigh
Bui, Cat N.
Cheng, Wei-Han
Miller, Catherine
Guerin, Annie
Maitland, Jessica
Ma, Esprit
Montez, Melissa
Grunspan, Moshe
Goldberg, Aaron D.
BLOOD, 2022, 140 : 11026 - 11028
[22] Clinical characteristics and outcome in IDH1/2 mutant AML patients - analysis of 5213 newly diagnosed patients with Acute Myeloid Leukemia
Middeke, M.
Metzeler, K. H.
Roellig, C.
Kramer, M.
Greif, P. A.
Spiekermann, K.
Krug, U.
Braess, J.
Kraemer, A.
Hochhaus, A.
Scholl, S.
Bruemmendorf, T. H.
Naumann, R.
Steffen, B.
Einsele, H.
Schaich, M.
Burchert, A.
Neubauer, A.
Schaefer-Eckart, K.
Goerlich, D.
Sauerland, C.
Schliemann, C.
Krause, S.
Haenel, M.
Frickhofen, N.
Noppeney, R.
Kaiser, U.
Baldus, C. D.
Kaufmann, M.
Stasik, S.
Woermann, B.
Sockel, K.
von Bonin, M.
Hiddemann, W.
Mueller-Tidow, C.
Platzbecker, U.
Berdel, W. E.
Bornhaeuser, M.
Serve, H.
Ehninger, G.
Schetelig, J.
Herold, T.
Stoelzel, F.
Thiede, C.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 295 - 296
[23] Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia
Middeke, Jan Moritz
Rollig, Christoph
Kramer, Michael
Kramer, Alwin
Bochtler, Tilman
Scholl, Sebastian
Hochhaus, Andreas
Jost, Edgar
Bruemmendorf, Tim H.
Naumann, Ralph
Steffen, Bjoern
Kunzmann, Volker
Einsele, Hermann
Schaich, Markus
Burchert, Andreas
Neubauer, Andreas
Schaefer-Eckart, Kerstin
Schliemann, Christoph
Krause, Stefan W.
Herbst, Regina
Haenel, Mathias
Frickhofen, Norbert
Noppeney, Richard
Kaiser, Ulrich
Baldus, Claudia D.
Kaufmann, Martin
Racil, Zdenek
Stasik, Sebastian
Sockel, Katja
von Bonin, Malte
Mueller-Tidow, Carsten
Platzbecker, Uwe
Berdel, Wolfgang E.
Mayer, Jiri
Serve, Hubert
Ehninger, Gerhard
Schetelig, Johannes
Thiede, Christian
Stoelzel, Friedrich
BLOOD, 2018, 132
[24] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
Short, Nicholas J.
Sedarati, Farhad
Zhao, Dan
Tsukurov, Olga
Friedlander, Sharon
Faller, Douglas V.
BLOOD, 2020, 136
[25] Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
Albliwi, Moath
Mustafa, Moaath K.
Nurse, Daniel P.
El-Asmar, Jessica
Batah, Heya
Abuamsha, Hasan
Rauf, Asaad
Hanna, John
Abu-Farsakh, Yomna
Bawwab, Ameed
Zabor, Emily C.
Bedelu, Yohana B.
Chen, Mark Jinan
Nakitandwe, Joy
Jain, Akriti G.
Gerds, Aaron T.
Balderman, Sophia
Molina, John C.
Mukherjee, Sudipto
Advani, Anjali S.
Carraway, Hetty E.
BLOOD, 2024, 144 : 1473 - 1474
[26] Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
Shen, Jingyi
Shan, Meng
Chu, Mengqian
Cai, Yiming
Rui, Jingwen
Chen, Suning
Wu, Depei
Xu, Yang
BLOOD CANCER JOURNAL, 2025, 15 (01):
[27] AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
Todisco, Elisabetta
Papayannidis, Cristina
Fracchiolla, Nicola
Petracci, Elisabetta
Zingaretti, Chiara
Vetro, Calogero
Martelli, Maria Paola
Zappasodi, Patrizia
Di Renzo, Nicola
Gallo, Susanna
Audisio, Ernesta
Griguolo, Davide
Cerchione, Claudio
Selleri, Carmine
Mattei, Daniele
Bernardi, Massimo
Fumagalli, Monica
Rizzuto, Giuliana
Facchini, Luca
Basilico, Claudia Maria
Manfra, Ilenia
Borlenghi, Erika
Cairoli, Roberto
Salutari, Prassede
Gottardi, Michele
Molteni, Alfredo
Martini, Vincenza
Lunghi, Monia
Fianchi, Luana
Cilloni, Daniela
Lanza, Francesco
Abruzzese, Elisabetta
Cascavilla, Nicola
Rivellini, Flavia
Ferrara, Felicetto
Maurillo, Luca
Nanni, Jacopo
Romano, Alessandra
Cardinali, Valeria
Gigli, Federica
Roncoroni, Elisa
Federico, Vincenzo
Marconi, Giovanni
Volpi, Roberta
Sciume, Mariarita
Tarella, Corrado
Rossi, Giuseppe
Martinelli, Giovanni
CANCER, 2023, 129 (07) : 992 - 1004
[28] Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States
Zeidan, Amer M.
Pollyea, Daniel A.
Borate, Uma
Vasconcelos, Alberto
Potluri, Ravi
Rotter, David
Kiendrebeogo, Zephirin
Gaugler, Lona
Bonifacio, Gaetano
Chen, Clara
BLOOD, 2021, 138
[29] Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia
Bewersdorf, Jan Philipp
Patel, Kishan K.
Goshua, George
Shallis, Rory Michael
Podoltsev, Nikolai A.
Stahl, Maximilian F.
Stempel, Jessica M.
Stein, Eytan
Huntington, Scott F.
Zeidan, Amer M.
BLOOD, 2022, 140
[30] Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
Bewersdorf, Jan Philipp
Patel, Kishan K. K.
Goshua, George
Shallis, Rory M. M.
Podoltsev, Nikolai A. A.
Stahl, Maximilian
Stein, Eytan M. M.
Huntington, Scott F. F.
Zeidan, Amer M. M.
LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 454 - 461

← 1 2 3 4 5 →